Brigatinib analog ALK-IN-1

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Brigatinib analog ALK-IN-1	Purity：98% min
CAS NO：1197958-12-5	Solubility：DMSO : 50 mg/mL (94.52 mM)
Molecular Formula：C₂₆H₃₄ClN₆O₂P	Package：Package according to customer requirements
Molecular Weight：529.014	Storage：Store at -20℃

Quality control

Remarks

Brigatinib-analog is an orally active, potent and selective anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) inhibitor. Brigatinib-analog is structurally related to Brigatinib (AP-26113). Brigatinib-analog binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells.

EGFR Inhibitors Related Products:

Erlotinib; Erlotinib hcl; Gefitinib; AG-490; Dacomitinib; WZ4002; Pelitinib; Allitinib; Rociletinib; Varlitinib; Icotinib; WHI-P154; CNX-2006; AG-18 ; Nazartinib

References

[1]. Sen Zhang, Frank Wang, Jeffrey Keats, Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Research: April 15, 2010; Volume 70, Issue 8, Supplement 1

[2]. Victor M. Rivera, Frank Wang, Rana Anjum, Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1